account_id none on file
legal_name Purple Biotech Ltd.
ticker PPBT
cik 1614744
domain purple-biotech.com
linkedin_company_url https://www.linkedin.com/company/6758085/
entry_point_account_id none on file
exchange Nasdaq
sector Health Care
sector index/company/sector/health-care/
calls 0 filings 11 executives 5 family 0
why_nownone on file
callsnone on file
filings
fund, annual recreation allowance, travel expenses payment and other conditions of employment. Israeli law generally requires severance pay, which may be funded by managers’ insurance and/or a pension fund, upon the retirement or death of an employee or termination of employment without cause (as defined in the Severance Pay Law, 5723-1963).
filing / Mar 19, 2026 / receipt
Much of the funding for expanded healthcare coverage may be sought through cost savings. While some of these savings may come from realizing greater efficiencies in delivering care, improving the effectiveness of preventive care and enhancing the overall quality of care, much of the cost savings may come from reducing the cost of care and increased enforcement activities.
filing / Mar 19, 2026 / receipt
as our Chief Financial Officer since May 2025. Mr. Lankry supports several companies as a strategic fractional Chief Financial Officer
filing / Mar 19, 2026 / receipt
to find cost savings in their clinical operations. Pharmaceuticals represent a significant portion of the cost of providing care.
filing / Mar 19, 2026 / receipt
Office lease USD thousands Balance as of January 1, 2025 164 Depreciation on right-to-use assets ( 200 ) Extension of a new lease agreement 258 Balance as of December 31, 2025 222 Balance as of January 1, 2024 316 Depreciation on right-to-use assets ( 152 ) Balance as of December 31, 2024 164 C.
filing / Mar 19, 2026 / receipt
in Israel, our office lease and payment to part of the service providers in Israel, are paid in NIS and in other currencies, such as
filing / Mar 19, 2026 / receipt
Shai Lankry | 49 | Chief Financial Officer
filing / Mar 19, 2026 / receipt
Gil Efron | Chief Executive Officer | $ | 390 | 134 | 45 | 568
filing / Mar 19, 2026 / receipt
Dr. Hadas Reuveni | Vice President of Research and Development | $ | 244 | 47 | 44 | 334
filing / Mar 19, 2026 / receipt
Dr. Michael Schickler | Head of Clinical and Regulatory Affairs | $ | 206 | 92 | 44 | 342
filing / Mar 19, 2026 / receipt
Isaac Israel | Director and Consultant | $ | 149 | - | 24 | 172
filing / Mar 19, 2026 / receipt
executives
| Dr. Hadas Reuveni | Vice President of Research and Development | - | receipt |
| Dr. Michael Schickler | Head of Clinical and Regulatory Affairs | - | receipt |
| GIL EFRON | Chief Executive Officer | - | receipt |
| Isaac Israel | Director and Consultant | - | receipt |
| Shai Lankry | Chief Financial Officer | - | receipt |
familynone on file
upcoming
| 2026-11-13 | earnings call | scheduled | ir |
changesnone on file
mcp_package_hint
slug purple-biotech-ltd
listing_url https://steadybase.io/company/data/index.json
mcp_url https://mcp.steadybase.io/mcp
steadybase-$